Central Role For Industry Beckons As Europe Rebuilds After COVID
Generics And Biosimilars Must Become A Central Policy Pillar, Says Rebecca Guntern
Generic and biosimilar medicines must become central to European healthcare policy as the region looks to rebuild in the wake of the COVID-19 pandemic, Medicines for Europe’s new president, Rebecca Guntern of Sandoz, tells Generics Bulletin in an exclusive interview.
